24
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Development of a functional HTS assay for the APJ receptor

, , , , &
Pages 39-47 | Published online: 19 Apr 2010

References

  • Carpene C, Dray C, Attane C, et al. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem. 2007;63(4):359–373.
  • Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ. J Neurochem. 2000;74(1):34–41.
  • Habata Y, Fujii R, Hosoya M, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta. 1999;1452(1):25–35.
  • De Mota N, Lenkei Z, Llorens-Cortes C. Cloning, pharmacological characterization and brain distribution of the rat apelin receptor. Neuroendocrinology. 2000;72(6):400–407.
  • Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ and its endogenous ligand apelin. J Neurochem. 2003;84(5):1162–1172.
  • Kasai A, Shintani N, Oda M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun. 2004;325(2):395–400.
  • Tiani C, Garcia-Pras E, Mejias M, et al. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol. 2009;50(2):296–305.
  • Hus-Citharel A, Bouby N, Frugiere A, et al. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 2008;74(4):486–494.
  • Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol. 2008;90(5):343–349.
  • O’Donnell LA, Agrawal A, Sabnekar P, et al. Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury. J Neurochem. 2007;102(6):1905–1917.
  • Zou MX, Liu HY, Haraguchi Y, et al. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBSLett. 2000;473(1):15–18.
  • Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol. 2008;75(10):1882–1892.
  • Iturrioz X, Alvear-Perez R, De Mota N, et al. Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 2009 Dec 29. [Epub ahead of print].
  • Kostenis E. Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci. 2001;22(11):560–564.
  • Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
  • Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ. Biochem Biophys Res Commun. 1998;251(2):471^476.
  • Llorens-Cortes C, Moos F. Opposite potentiality of hypothalamic coexpressed neuropeptides, apelin and vasopressin in maintaining body-fluid homeostasis. Prog Brain Res. 2008;170:559–570.
  • Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107(2):198–211.
  • Bai B, Tang J, Liu H, et al. Apelin-13 induces ERK1/2 but not p38 MAPK activation through coupling of the human apelin receptor to the Gi2 pathway. Acta Biochim Biophys Sin (Shanghai). 2008;40(4):311–318.
  • Guo L, Li Q, Wang W, et al. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res. 2009;34(4):142–154.
  • Hosoya M, Kawamata Y, Fukusumi S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000;275(28):21061–21067.
  • Seyedabadi M, Goodchild AK, Pilowsky PM. Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration. Auton Neurosci. 2002;101(1–2):32–38.
  • Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146(1):231–236.